ASN 002

Drug Profile

ASN 002

Alternative Names: ASN002

Latest Information Update: 19 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Asana BioSciences
  • Class Antineoplastics; Antirheumatics; Skin disorder therapies; Small molecules
  • Mechanism of Action Janus kinase inhibitors; Syk kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atopic dermatitis; Chronic lymphocytic leukaemia; Myelofibrosis; Non-Hodgkin's lymphoma
  • Phase I/II Solid tumours
  • Preclinical Rheumatoid arthritis

Most Recent Events

  • 19 Jul 2018 Chemical structure information added
  • 01 Jun 2018 Interim pharmacodynamics, pharmacokinetics, adverse events and efficacy data from a phase I/II trial in Solid tumors presented at the 54th Annual Meeting of the American Society of Clinical Oncology
  • 01 Jun 2018 Phase-II clinical trials in Atopic dermatitis (Treatment-experienced) in Canada, USA (PO) (NCT03531957)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top